Drug Type Monoclonal antibody |
Synonyms NTX 2R13 |
Target |
Mechanism CD112R antagonists(Transmembrane protein PVRIG antagonists), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), T lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Nectin Therapeutics Ltd.Startup |
Active Organization Nectin Therapeutics Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Solid tumor | Preclinical | US | Nectin Therapeutics Ltd.Startup | - |